Is Eli Lilly and Company FDA approved?

Eli Lilly and Company holds 10 FDA-registered establishments across 5 countries. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.

Where are Eli Lilly and Company's drugs manufactured?

At registered sites in Spain, France, Ireland, Italy, the United States. The FDA register lists Madrid; Fegersheim; Kinsale; Sesto Fiorentino; Carolina, PR; Concord, NC, and 3 more. Registered operations: analytical testing, active ingredient (API) manufacture, labelling, finished drug manufacture, packaging.

What drugs does Eli Lilly and Company make?

189 products are listed under Eli Lilly and Company in the openFDA NDC Directory, most often as injection, solution; injection, suspension; tablet, film coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.

Eli Lilly and Company

Data as of 24 Sept 2026 · How to read this entry

Request a quote Claim this profile

Registered sites: 10
Active NDC listings: 186
Live patents: 388
Exclusivities: 12
Shortage listings: 17
Countries: 5
Base: United States

Authorisation

Registered operations

Analytical testing10Active ingredient (API) manufacture3Labelling6Finished drug manufacture8Packaging6

Sites

Registered establishments

Establishment	Address	Registered for	FEI / DUNS
Lilly S.A.Registrant: Eli Lilly and Company	Avda. De la Industria, 30, Alcobendas, Madrid, 28108, Spain (ESP)	Analytical testing, Finished drug manufacture	3000235541462010034
Lilly FranceRegistrant: Eli Lilly and Company	Z.A.-Centre de production, 2 rue du Colonel Lilly, Fegersheim, 67640, France (FRA)	Analytical testing, Labelling, Finished drug manufacture, Packaging	3002807475395346919
Eli Lilly Kinsale LimitedRegistrant: Eli Lilly and Company	Dunderrow, Kinsale, Co Cork , Ireland (IRL)	Analytical testing, Active ingredient (API) manufacture	3002806888985672710
Eli Lilly Italia SPARegistrant: Eli Lilly and Company	Via Antonio Gramsci 731/733, Sesto Fiorentino, FI 50019, Italy (ITA)	Analytical testing, Labelling, Finished drug manufacture, Packaging	3002806895428316723
Lilly del Caribe, Inc.Registrant: Eli Lilly and Company	12.6 KM 65th Infantry Road (PR01), Carolina, Puerto Rico (PR) 00985, United States (USA)	Analytical testing, Finished drug manufacture	2619243806917345
Lilly del Caribe, Inc.Registrant: Eli Lilly and Company	12.3 KM 65th Infantry Road (PR05), Carolina, Puerto Rico (PR) 00985, United States (USA)	Analytical testing, Active ingredient (API) manufacture	3004525072828519616
Eli Lilly and Company	1420 Concord Parkway S, Concord, North Carolina (NC) 28027, United States (USA)	Analytical testing, Labelling, Finished drug manufacture, Packaging	3027403675119015895
Eli Lilly and Company	59 Moore Dr, Durham, North Carolina (NC) 27713, United States (USA)	Analytical testing, Labelling, Finished drug manufacture, Packaging	3020952692118750267
Eli Lilly and Company	Lilly Corporate Center, Indianapolis, Indiana (IN) 46285, United States (USA)	Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging	1819470006421325
Eli Lilly and Company	10300 128th Ave, Pleasant Prairie, Wisconsin (WI) 53158, United States (USA)	Analytical testing, Labelling, Finished drug manufacture, Packaging	3031961517118291262

Alert

Drug shortage listings

Drug	Presentation	Status	Availability	Posted / updated
Insulin Glargine-aglr InjectionEndocrinology/Metabolism	Rezvoglar, Injection, 100 [iU]/1 mL (NDC 0002-8980-05)	To Be Discontinued	-	1 Sept 20261 Sept 2026
Insulin Lispro InjectionEndocrinology/Metabolism	Insulin Lispro Junior KwikPen, Injection, 100 [iU]/1 mL (NDC 0002-7752-05)	To Be Discontinued	-	1 Sept 20261 Sept 2026
Insulin Lispro Protamine and Insulin Lispro InjectionEndocrinology/Metabolism	Humalog Mix 75/25, Injection, 100 [iU]/1 mL (NDC 0002-8233-05)	To Be Discontinued	-	1 Sept 20261 Sept 2026
Mirikizumab-mrkz InjectionGastroenterology, Other	Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27)	To Be Discontinued	-	22 Dec 202522 Dec 2025
Mirikizumab-mrkz InjectionGastroenterology, Other	Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27)	To Be Discontinued	-	22 Dec 202522 Dec 2025
Lasmiditan Succinate TabletNeurology	Reyvow, Tablet, 100 mg (NDC 0002-4491-08)	To Be Discontinued	-	3 Nov 20253 Nov 2025
Lasmiditan Succinate TabletNeurology	Reyvow, Tablet, 50 mg (NDC 0002-4312-61)	To Be Discontinued	-	3 Nov 20253 Nov 2025
Lasmiditan Succinate TabletNeurology	Reyvow, Tablet, 100 mg (NDC 0002-4491-61)	To Be Discontinued	-	3 Nov 20253 Nov 2025
Lasmiditan Succinate TabletNeurology	Reyvow, Tablet, 100 mg (NDC 0002-4491-62)	To Be Discontinued	-	3 Nov 20253 Nov 2025
Lasmiditan Succinate TabletNeurology	Reyvow, Tablet, 50 mg (NDC 0002-4312-08)	To Be Discontinued	-	3 Nov 20253 Nov 2025
Lasmiditan Succinate TabletNeurology	Reyvow, Tablet, 50 mg (NDC 0002-4312-62)	To Be Discontinued	-	3 Nov 20253 Nov 2025
Insulin Glargine InjectionEndocrinology/Metabolism	Basaglar, Injection, U-100 Tempo Pen (NDC 0002-8214-05)	To Be Discontinued	-	24 Oct 202524 Oct 2025
Insulin Lispro InjectionEndocrinology/Metabolism	Humalog, Injection, U-100 Tempo Pen (NDC 0002-8213-05)	To Be Discontinued	-	24 Oct 202524 Oct 2025
Insulin Lispro-aabc InjectionEndocrinology/Metabolism	Lyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99)	To Be Discontinued	-	24 Oct 202524 Oct 2025
Insulin Lispro-aabc InjectionEndocrinology/Metabolism	Lyumjev, Injection, U-100 Tempo Pen (NDC 0002-8235-05)	To Be Discontinued	-	24 Oct 202524 Oct 2025
Pemetrexed Disodium InjectionOncology	Alimta, Injection, 500 mg/20 mL (NDC 0002-7623-01)	To Be Discontinued	-	16 Oct 202516 Oct 2025
Pemetrexed Disodium InjectionOncology	Alimta, Injection, 100 mg/4 mL (NDC 0002-7640-01)	To Be Discontinued	-	16 Oct 202516 Oct 2025

Catalogue

Drug listings by form and route

186

186 active NDC listings: 138 human prescription drug, 37 drug for further processing, 6 human otc drug, 5 bulk ingredient. By marketing category: NDA 89, BLA 54, DRUG FOR FURTHER PROCESSING 37, BULK INGREDIENT 5, EMERGENCY USE AUTHORIZATION 1.

Dosage form	NDCs
injection, solution	111
injection, suspension	15
tablet, film coated	14
capsule	11
tablet, coated	10
tablet	7
kit	5
crystal	4
injection, powder, lyophilized, for solution	4
solution	4
powder	1

Route	NDCs
subcutaneous	100
oral	36
intravenous	14
intramuscular	3
parenteral	2

Labeller name on the listing	NDCs
eli lilly and company	186

Exclusivity

Patents and exclusivities

388

Patent	Product	Covers	Expiry
8419307	AXIRONtestosterone	use	Feb 2027
8807861	AXIRONtestosterone	product	Feb 2027
9289586	AXIRONtestosterone	use	Feb 2027
8435944	AXIRONtestosterone	use	Sept 2027
7423050	REYVOWlasmiditan succinate	substance, product	Feb 2028
8420629	OLUMIANTbaricitinib	use	Mar 2029
12257246	REYVOWlasmiditan succinate	use	Jul 2030
7855211	VERZENIOabemaciclib	substance, product	Sept 2031
11806555	OLUMIANTbaricitinib	use	Nov 2031
9737469	OLUMIANTbaricitinib	use	Nov 2031
8158616	OLUMIANTbaricitinib	substance, product	May 2032
11045474	OLUMIANTbaricitinib	use	Nov 2032
9089574	OLUMIANTbaricitinib	use	Nov 2032
9474780	MOUNJARO, MOUNJARO (AUTOINJECTOR), MOUNJARO KWIKPEN, ZEPBOUND, ZEPBOUND (AUTOINJECTOR), ZEPBOUND KWIKPENtirzepatide	substance, product	May 2036
RE50455	FOUNDAYOorforglipron calcium	substance, product	Sept 2037
10112942	RETEVMOselpercatinib	substance, product	Oct 2037
10137124	RETEVMOselpercatinib	use	Oct 2037
10172851	RETEVMOselpercatinib	use	Oct 2037
11053214	REYVOWlasmiditan succinate	substance, product	Dec 2037
10112942*PED	RETEVMOselpercatinib	use	Apr 2038
10137124*PED	RETEVMOselpercatinib	use	Apr 2038
10172851*PED	RETEVMOselpercatinib	use	Apr 2038
10584124	RETEVMOselpercatinib	substance	Oct 2038
10786489	RETEVMOselpercatinib	product	Oct 2038
12138250	RETEVMOselpercatinib	use	Oct 2038
10584124*PED	RETEVMOselpercatinib	use	Apr 2039
10786489*PED	RETEVMOselpercatinib	use	Apr 2039
12138250*PED	RETEVMOselpercatinib	use	Apr 2039
11357820	MOUNJARO, MOUNJARO (AUTOINJECTOR), ZEPBOUND, ZEPBOUND (AUTOINJECTOR)tirzepatide	substance, product	Jun 2039
11918623	ZEPBOUND, ZEPBOUND (AUTOINJECTOR)tirzepatide	use	Jun 2039
12453755	MOUNJARO, MOUNJARO (AUTOINJECTOR)tirzepatide	use	Jun 2039
12453756	MOUNJARO, MOUNJARO (AUTOINJECTOR), ZEPBOUND, ZEPBOUND (AUTOINJECTOR)tirzepatide	product	Jun 2039
12629404	MOUNJARO, MOUNJARO (AUTOINJECTOR), ZEPBOUND, ZEPBOUND (AUTOINJECTOR)tirzepatide	product	Jun 2039
10654866	INLURIYOimlunestrant tosylate	substance, product	Jul 2039
11117902	INLURIYOimlunestrant tosylate	substance, product	Jul 2039
12343382	MOUNJARO, MOUNJARO (AUTOINJECTOR), MOUNJARO KWIKPEN, ZEPBOUND, ZEPBOUND (AUTOINJECTOR), ZEPBOUND KWIKPENtirzepatide	use	Jul 2039
12453758	ZEPBOUND, ZEPBOUND (AUTOINJECTOR), ZEPBOUND KWIKPENtirzepatide	use	Jul 2039
12616740	MOUNJARO, MOUNJARO (AUTOINJECTOR), MOUNJARO KWIKPEN, ZEPBOUND, ZEPBOUND (AUTOINJECTOR), ZEPBOUND KWIKPENtirzepatide	use	Jul 2039
12071423	REYVOWlasmiditan succinate	product	Jul 2040
12295987	MOUNJARO, MOUNJARO (AUTOINJECTOR), MOUNJARO KWIKPENtirzepatide	use	Dec 2041

Product	Exclusivity	Until
FOUNDAYOORFORGLIPRON CALCIUM	NCE New chemical entity	Apr 2031
INLURIYOIMLUNESTRANT TOSYLATE	NCE New chemical entity	Sept 2030
MOUNJAROTIRZEPATIDE	NCE New chemical entity	May 2027
MOUNJAROTIRZEPATIDE	NPP New patient population	Dec 2028
MOUNJARO (AUTOINJECTOR)TIRZEPATIDE	NCE New chemical entity	May 2027
MOUNJARO (AUTOINJECTOR)TIRZEPATIDE	NPP New patient population	Dec 2028
MOUNJARO KWIKPENTIRZEPATIDE	NCE New chemical entity	May 2027
MOUNJARO KWIKPENTIRZEPATIDE	NPP New patient population	Dec 2028
RETEVMOSELPERCATINIB	PED Paediatric	Nov 2031
ZEPBOUNDTIRZEPATIDE	I-958 New indication	Dec 2027
ZEPBOUND (AUTOINJECTOR)TIRZEPATIDE	I-958 New indication	Dec 2027
ZEPBOUND KWIKPENTIRZEPATIDE	I-958 New indication	Dec 2027

Catalogue

Marketed products

189

Showing 150 of 189.

Brand	Generic name	Form / route	NDC
Alimta	Pemetrexed disodium	injection, powder, lyophilized, for solution, intravenous	0002-7623NDA
Alimta	Pemetrexed disodium	injection, powder, lyophilized, for solution, intravenous	0002-7640NDA
Amyvid	Florbetapir F 18	injection, solution, intravenous	0002-1200NDA
BASAGLAR KwikPen	Insulin glargine	injection, solution, subcutaneous	0002-7715BLA
Baricitinib	baricitinib	tablet, film coated, oral	0002-6885EMERGENCY USE AUTHORIZATION
CYRAMZA	ramucirumab	solution, intravenous	0002-7669BLA
CYRAMZA	ramucirumab	solution, intravenous	0002-7678BLA
Cialis	Tadalafil	tablet, film coated, oral	0002-4462NDA
Cialis	Tadalafil	tablet, film coated, oral	0002-4463NDA
Cialis	Tadalafil	tablet, film coated, oral	0002-4464NDA
-	Dulaglutide	injection, solution	0002-1401DRUG FOR FURTHER PROCESSING
-	Dulaglutide	injection, solution	0002-1402DRUG FOR FURTHER PROCESSING
EBGLYSS	lebrikizumab-lbkz	injection, solution, subcutaneous	0002-7772BLA
EBGLYSS	lebrikizumab-lbkz	injection, solution, subcutaneous	0002-7797BLA
EMGALITY	galcanezumab-gnlm	injection, solution, subcutaneous	0002-1436BLA
EMGALITY	galcanezumab-gnlm	injection, solution, subcutaneous	0002-2377BLA
Evista	Raloxifene hydrochloride	tablet, oral	0002-4184NDA
FOUNDAYO	orforglipron	tablet, film coated, oral	0002-4178NDA
FOUNDAYO	orforglipron	tablet, film coated, oral	0002-4503NDA
FOUNDAYO	orforglipron	tablet, film coated, oral	0002-4794NDA
FOUNDAYO	orforglipron	tablet, film coated, oral	0002-4803NDA
FOUNDAYO	orforglipron	tablet, film coated, oral	0002-4839NDA
FOUNDAYO	orforglipron	tablet, film coated, oral	0002-4953NDA
Forteo	Teriparatide	injection, solution, subcutaneous	0002-8400NDA
Forteo	Teriparatide	injection, solution, subcutaneous	0002-9678NDA
HUMATROPE	Somatropin	kit, intramuscular, subcutaneous	0002-8147BLA
HUMATROPE	Somatropin	kit, intramuscular, subcutaneous	0002-8148BLA
HUMATROPE	Somatropin	kit, intramuscular, subcutaneous	0002-8149BLA
Humalog	Insulin lispro	injection, solution, intravenous, subcutaneous	0002-7510BLA
Humalog	Insulin lispro	injection, solution, intravenous, subcutaneous	0002-7516BLA
Humalog Junior KwikPen	Insulin lispro	injection, solution, subcutaneous	0002-7714BLA
Humalog KwikPen	Insulin lispro	injection, solution, subcutaneous	0002-7712BLA
Humalog KwikPen	Insulin lispro	injection, solution, intravenous, subcutaneous	0002-8799BLA
Humalog Mix50/50 KwikPen	Insulin lispro	injection, suspension, subcutaneous	0002-8798BLA
Humalog Mix75/25	Insulin lispro	injection, suspension, subcutaneous	0002-7511BLA
Humalog Mix75/25 KwikPen	Insulin lispro	injection, suspension, subcutaneous	0002-8797BLA
Humalog Tempo Pen	Insulin lispro	injection, solution, subcutaneous	0002-8213BLA
Humulin 70/30	Insulin human	injection, suspension, subcutaneous	0002-8715BLA
Humulin 70/30 KwikPen	Insulin human	injection, suspension, subcutaneous	0002-8803BLA
Humulin N	Insulin human	injection, suspension, subcutaneous	0002-8315BLA
Humulin N	Insulin human	injection, suspension, subcutaneous	0002-8805BLA
Humulin R	Insulin human	injection, solution, parenteral	0002-0213BLA
Humulin R	Insulin human	injection, solution, parenteral	0002-8215BLA
Humulin R U-500	Insulin human	injection, solution, subcutaneous	0002-8501BLA
Humulin R U-500 KwikPen	Insulin human	injection, solution, subcutaneous	0002-8824BLA
Inluriyo	imlunestrant	tablet, film coated, oral	0002-1717NDA
Insulin Lispro	Insulin lispro	injection, solution, intravenous, subcutaneous	0002-7737BLA
Insulin Lispro Junior KwikPen	Insulin lispro	injection, solution, subcutaneous	0002-7752BLA
Insulin Lispro KwikPen	Insulin lispro	injection, solution, intravenous, subcutaneous	0002-8222BLA
Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen	Insulin lispro	injection, suspension, subcutaneous	0002-8233BLA
-	Insulin glargine	injection, solution	0002-1076DRUG FOR FURTHER PROCESSING
-	Insulin glargine	injection, solution	0002-1437DRUG FOR FURTHER PROCESSING
-	Insulin glargine	crystal	0002-9524BULK INGREDIENT
-	Insulin human	injection, solution	0002-0013DRUG FOR FURTHER PROCESSING
-	Insulin human	injection, solution	0002-0095DRUG FOR FURTHER PROCESSING
-	Insulin human	injection, solution	0002-0096DRUG FOR FURTHER PROCESSING
-	Insulin human	injection, suspension	0002-0113DRUG FOR FURTHER PROCESSING
-	Insulin human	injection, suspension	0002-0119DRUG FOR FURTHER PROCESSING
-	Insulin human	crystal	0002-0485BULK INGREDIENT
-	Insulin human	injection, suspension	0002-2045DRUG FOR FURTHER PROCESSING
-	Insulin human	injection, suspension	0002-2510DRUG FOR FURTHER PROCESSING
-	Insulin human	crystal	0002-9307BULK INGREDIENT
-	Insulin lispro	injection, suspension	0002-0121DRUG FOR FURTHER PROCESSING
-	Insulin lispro	injection, suspension	0002-0124DRUG FOR FURTHER PROCESSING
-	Insulin lispro	injection, suspension	0002-0137DRUG FOR FURTHER PROCESSING
-	Insulin lispro	crystal	0002-0535BULK INGREDIENT
-	Insulin lispro	injection, solution	0002-1099DRUG FOR FURTHER PROCESSING
-	Insulin lispro	injection, solution	0002-1455DRUG FOR FURTHER PROCESSING
-	Insulin lispro	injection, solution	0002-2499DRUG FOR FURTHER PROCESSING
-	Insulin lispro	injection, solution	0002-2576DRUG FOR FURTHER PROCESSING
-	Insulin lispro	injection, solution	0002-6007DRUG FOR FURTHER PROCESSING
-	Insulin lispro-aabc	injection, solution	0002-0872DRUG FOR FURTHER PROCESSING
-	Insulin lispro-aabc	injection, solution	0002-2415DRUG FOR FURTHER PROCESSING
-	Insulin lispro-aabc	injection, solution	0002-2479DRUG FOR FURTHER PROCESSING
-	Insulin lispro-aabc	injection, solution	0002-2509DRUG FOR FURTHER PROCESSING
-	Insulin lispro-aabc	injection, solution	0002-2572DRUG FOR FURTHER PROCESSING
-	Insulin lispro-aabc	injection, solution	0002-2578DRUG FOR FURTHER PROCESSING
JAYPIRCA	pirtobrutinib	tablet, coated, oral	0002-6902NDA
JAYPIRCA	pirtobrutinib	tablet, coated, oral	0002-7026NDA
Kisunla	donanemab-azbt	injection, solution, intravenous	0002-9401BLA
LYUMJEV	Insulin lispro-aabc	injection, solution, subcutaneous	0002-7726BLA
LYUMJEV	Insulin lispro-aabc	injection, solution, intravenous, subcutaneous	0002-7728BLA
LYUMJEV Junior KwikPen	Insulin lispro-aabc	injection, solution, subcutaneous	0002-8351BLA
LYUMJEV KwikPen	Insulin lispro-aabc	injection, solution, subcutaneous	0002-8207BLA
LYUMJEV KwikPen	Insulin lispro-aabc	injection, solution, subcutaneous	0002-8228BLA
LYUMJEV Tempo Pen	Insulin lispro-aabc	injection, solution, subcutaneous	0002-8235BLA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-1152NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-1243NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-1457NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-1460NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-1471NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-1484NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-1495NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-1506NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-2214NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-2340NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-2423NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-3002NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-4052NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-4103NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-4210NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-4304NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-4523NDA
Mounjaro	tirzepatide	injection, solution, subcutaneous	0002-4612NDA
Mounjaro KwikPen	tirzepatide	injection, solution, subcutaneous	0002-3411NDA
Mounjaro KwikPen	tirzepatide	injection, solution, subcutaneous	0002-3422NDA
Mounjaro KwikPen	tirzepatide	injection, solution, subcutaneous	0002-3433NDA
Mounjaro KwikPen	tirzepatide	injection, solution, subcutaneous	0002-3444NDA
Mounjaro KwikPen	tirzepatide	injection, solution, subcutaneous	0002-3455NDA
Mounjaro KwikPen	tirzepatide	injection, solution, subcutaneous	0002-3466NDA
Olumiant	baricitinib	tablet, film coated, oral	0002-4182NDA
Olumiant	baricitinib	tablet, film coated, oral	0002-4479NDA
Olumiant	baricitinib	tablet, film coated, oral	0002-4732NDA
Omvoh	mirikizumab-mrkz	injection, solution, subcutaneous	0002-1442BLA
Omvoh	mirikizumab-mrkz	injection, solution, subcutaneous	0002-3116BLA
Omvoh	mirikizumab-mrkz	injection, solution, intravenous	0002-7575BLA
Omvoh	mirikizumab-mrkz	kit, subcutaneous, subcutaneous	0002-7717BLA
Omvoh	mirikizumab-mrkz	kit, subcutaneous, subcutaneous	0002-7722BLA
Omvoh	mirikizumab-mrkz	injection, solution, subcutaneous	0002-8011BLA
Omvoh	mirikizumab-mrkz	injection, solution, subcutaneous	0002-8870BLA
-	Pemetrexed disodium	injection, powder, lyophilized, for solution	0002-2059DRUG FOR FURTHER PROCESSING
-	Pemetrexed disodium	injection, powder, lyophilized, for solution	0002-2060DRUG FOR FURTHER PROCESSING
RETEVMO	selpercatinib	capsule, oral	0002-2980NDA
RETEVMO	selpercatinib	capsule, oral	0002-3977NDA
RETEVMO	selpercatinib	tablet, coated, oral	0002-5340NDA
RETEVMO	selpercatinib	tablet, coated, oral	0002-5562NDA
RETEVMO	selpercatinib	tablet, coated, oral	0002-6082NDA
RETEVMO	selpercatinib	tablet, coated, oral	0002-6120NDA
Reyvow	lasmiditan	tablet, oral	0002-4312NDA
Reyvow	lasmiditan	tablet, oral	0002-4491NDA
Rezvoglar KwikPen	Insulin glargine-aglr	injection, solution, subcutaneous	0002-8980BLA
Strattera	Atomoxetine hydrochloride	capsule, oral	0002-3227NDA
Strattera	Atomoxetine hydrochloride	capsule, oral	0002-3228NDA
Strattera	Atomoxetine hydrochloride	capsule, oral	0002-3229NDA
Strattera	Atomoxetine hydrochloride	capsule, oral	0002-3238NDA
Strattera	Atomoxetine hydrochloride	capsule, oral	0002-3239NDA
Strattera	Atomoxetine hydrochloride	capsule, oral	0002-3250NDA
Strattera	Atomoxetine hydrochloride	capsule, oral	0002-3251NDA
TALTZ	ixekizumab	injection, solution, subcutaneous	0002-1445BLA
TALTZ	ixekizumab	injection, solution, subcutaneous	0002-7724BLA
TALTZ	ixekizumab	injection, solution, subcutaneous	0002-8900BLA
TALTZ	ixekizumab	injection, solution, subcutaneous	0002-8905BLA
TAUVID	Flortaucipir F-18	injection, solution, intravenous	0002-1220NDA
Trulicity	Dulaglutide	injection, solution, subcutaneous	0002-1433BLA
Trulicity	Dulaglutide	injection, solution, subcutaneous	0002-1434BLA
Trulicity	Dulaglutide	injection, solution, subcutaneous	0002-2236BLA
Trulicity	Dulaglutide	injection, solution, subcutaneous	0002-3182BLA
Verzenio	abemaciclib	tablet, oral	0002-4483NDA
Verzenio	abemaciclib	tablet, oral	0002-4815NDA
Verzenio	abemaciclib	tablet, oral	0002-5337NDA

Neighbours

Registered in the same town

Almac Clinical Services, LLCDurham, NC · 3 sites
PETNET Solutions, Inc.DURHAM, NC; INDIANAPOLIS, IN · 2 sites
Cardinal Health 418, Inc.Indianapolis, IN · 2 sites
Merck & Co., Inc.Durham, NC · 2 sites
Novartis Pharmaceuticals CorporationIndianapolis, IN · 2 sites
KBI Biopharma, Inc.Durham, NC · 2 sites
Novo Nordisk Inc.Durham, NC
Hospira, Inc.Pleasant Prairie, WI
Encube Ethicals LimitedDurham, NC
Oxford Biomedica (UK) LimitedDurham, NC
ROVI Pharma Industrial Services S.A.Madrid, ESP
United Therapeutics CorporationDurham, NC

Compare

Comparable companies in United States

Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.10 sites · 30 NDC
Medical-technical Gases, Inc.10 sites · 7 NDC
Alcami Carolinas Corporation10 sites · 1 NDC
The Procter & Gamble Manufacturing Company11 sites · 849 NDC
Amgen, Inc9 sites · 105 NDC
Zoetis Inc11 sites · 29 NDC
Pfizer Inc11 sites · 27 NDC
Sotera Health LLC11 sites · 2 NDC
Haleon US Holdings LLC8 sites · 405 NDC
Genentech, Inc.8 sites · 93 NDC

Enquiry

Common questions

Is Eli Lilly and Company FDA approved?: Eli Lilly and Company holds 10 FDA-registered establishments across 5 countries. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
Where are Eli Lilly and Company's drugs manufactured?: At registered sites in Spain, France, Ireland, Italy, the United States. The FDA register lists Madrid; Fegersheim; Kinsale; Sesto Fiorentino; Carolina, PR; Concord, NC, and 3 more. Registered operations: analytical testing, active ingredient (API) manufacture, labelling, finished drug manufacture, packaging.
What drugs does Eli Lilly and Company make?: 189 products are listed under Eli Lilly and Company in the openFDA NDC Directory, most often as injection, solution; injection, suspension; tablet, film coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.

Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.